ERBB2 and breast carcinoma: In a phase III randomized controlled study of early-stage breast cancer (78), metformin combined with a standard treatment showed significant overall survival and invasive DFS benefits over the placebo with a standard treatment in HER2-positive breast cancer (P = 0.038 and 0.0026, respectively).